Allist(SH:688578) Jin Rong Jie·2025-04-15 11:07Group 1 - The core viewpoint of the articles highlights the performance and market position of Ailis, a company focused on innovative cancer treatment drugs, particularly in the non-small cell lung cancer sector [1][2] - As of April 15, Ailis closed at 86.63 yuan, down 1.33%, with a rolling price-to-earnings (PE) ratio of 27.37 times, and a total market capitalization of 38.983 billion yuan [1] - The average PE ratio for the chemical pharmaceutical industry is 45.73 times, with a median of 25.62 times, placing Ailis at the 95th position in the industry ranking [1][2] Group 2 - As of the third quarter of 2024, 367 institutions hold shares in Ailis, with a total of 40.9648 million shares valued at 2.454 billion yuan [1] - Ailis has developed a rich pipeline in the field of small molecule targeted drugs for non-small cell lung cancer, with its main products including Aifuratinib (a third-generation EGFR-TKI) and Alisartan [1] - The latest financial results show that for the third quarter of 2024, Ailis achieved a revenue of 2.533 billion yuan, a year-on-year increase of 87.97%, and a net profit of 1.063 billion yuan, a year-on-year increase of 158.99%, with a gross profit margin of 95.80% [1]